Weatherly Asset Management L. P. Sells 1,742 Shares of Johnson & Johnson (NYSE:JNJ)

Weatherly Asset Management L. P. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 48,567 shares of the company’s stock after selling 1,742 shares during the quarter. Johnson & Johnson accounts for about 1.2% of Weatherly Asset Management L. P.’s holdings, making the stock its 20th largest position. Weatherly Asset Management L. P.’s holdings in Johnson & Johnson were worth $8,579,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Geller Advisors LLC boosted its position in shares of Johnson & Johnson by 7.5% in the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after acquiring an additional 648 shares during the period. Lincoln Capital Corp lifted its stake in Johnson & Johnson by 15.9% in the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after purchasing an additional 183 shares in the last quarter. Ieq Capital LLC boosted its holdings in Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after purchasing an additional 6,154 shares during the period. Ranch Capital Advisors Inc. grew its position in shares of Johnson & Johnson by 3.2% during the 2nd quarter. Ranch Capital Advisors Inc. now owns 10,154 shares of the company’s stock valued at $1,802,000 after purchasing an additional 318 shares in the last quarter. Finally, RFG Advisory LLC raised its position in shares of Johnson & Johnson by 2.7% in the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after buying an additional 594 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on JNJ shares. Citigroup upped their target price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Piper Sandler lowered their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Atlantic Securities boosted their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 25th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, SVB Leerink cut their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $174.73.

Insiders Place Their Bets

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Down 1.1 %

Shares of NYSE:JNJ opened at $152.38 on Friday. The stock has a market capitalization of $396.84 billion, a P/E ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54. The stock’s 50-day moving average price is $161.97 and its 200-day moving average price is $167.91. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a 12-month low of $150.71 and a 12-month high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same period last year, the company earned $2.13 EPS. Johnson & Johnson’s revenue for the quarter was down 4.4% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. The ex-dividend date was Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.97%. Johnson & Johnson’s payout ratio is currently 67.06%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.